Last Updated : May 4, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort ascending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Xolair | Omalizumab | Asthma, severe persistent | Cancelled | |||
| Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled | |||
| Cyramza | Ramucirumab | Cancelled | ||||
| Imbruvica | Ibrutinib | |||||
| Xofluza | baloxavir marboxil | Influenza | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | |||
| Imbruvica | ibrutinib | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer |
Last Updated : May 4, 2024